News and Updates

Our Statement on Deceased Donor Islet Cell Availability & The ISLET Act Curing type 1 diabetes (T1D) is Breakthrough T1D’s number one priority. As the leading global T1D research and advocacy organization, we are currently funding over $450 million in cures research in 23 countries. Everything we do is focused on making cures happen for the T1D […]

There are three ways we can get to cures for type 1 diabetes faster: cell therapies, early detection, and disease-modifying therapies.

Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.

Breakthrough T1D, Breakthrough T1D Canada, and the Stem Cell Network (SCN) have partnered to support cell therapy research in Canada.

This meeting focused on the role of the EU in addressing the needs of the T1D community and accelerating T1D breakthroughs.

The Center has been renamed The Breakthrough T1D Barbara Dewey Cammett Center of Excellence in New England.

Breakthrough T1D's Medical Affairs team hosted experts in islet transplantation to discuss a clinical roadmap for manufactured cell therapies.

Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how we’re going to make them a reality.

Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to unlock access to manufactured islet therapies for people with T1D.

Breakthrough T1D's new Medical Affairs unit will address the numerous challenges contributing to the slow adoption of groundbreaking T1D therapies.